1 ior enlargement, is narrower and essentially adynamic.

2 ere is concern that these drugs might induce adynamic bone disease (ABD).

3 the odds ratio (95% confidence interval) for adynamic bone disease (maximum PTH <150 pg/ml) was 0.26

4 ociated with decreased bone mineral density, adynamic bone disease, and fractures.

5                      At 6 mo, all of PAM had adynamic bone disease, whereas 50% of CON continued to h

6 There was no evidence for the development of adynamic bone disease.

7 hyperparathyroid bone disease and whites for adynamic bone disease.

8  of bone turnover and increased incidence of adynamic bone disease.

9                                           An adynamic bone disorder (ABD) is an important complicatio

10      The CKD in this model is associated the adynamic bone disorder form of renal osteodystrophy.

11 g this model, however, is complicated by the adynamic bone disorder; both calcitriol and paricalcitol

12                 Whether an improved BMD with adynamic bone histology is useful in maintaining long-te

13 treatment was associated with development of adynamic bone histology.

14      The risk of inducing low bone turnover (adynamic bone) seems to be quite low with 10.4% of alfac

15 s have been implicated in the development of adynamic bone, including the use of calcium-containing p

16 ially by osteomalacia and, more recently, by adynamic or aplastic bone disease.